
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
BiotechTV - News
00:00
Intro
BiotechTV introduces its Basel tour, sponsored by the Basel Area Life Sciences Supercluster.
Play episode from 00:00
Transcript


